We serve Chemical Name:5-methylisoxazol CAS:5765-44-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-methylisoxazol
CAS.NO:5765-44-6
Synonyms:MFCD00003152;5-Methyl-1,2-oxazole;Isoxazole, 5-methyl-;5-methylisoxazol;EINECS 227-289-8;5-Methyl isoxazole
Molecular Formula:C4H5NO
Molecular Weight:83.089
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:122.7±9.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.438
PSA:26.03000
Exact Mass:83.037117
LogP:0.54
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:1993
Packing Group:III
Contact us for information like MFCD00003152 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Methyl isoxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 227-289-8 Use and application,MFCD00003152 technical grade,usp/ep/jp grade.
Related News: On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business. 5-methylisoxazol manufacturer If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such. 5-methylisoxazol supplier Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 5-methylisoxazol vendor The injection has previously proven to be as effective as standard daily pills with three active ingredients when administered monthly and also once every two months. 5-methylisoxazol factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.
